83 related articles for article (PubMed ID: 19580952)
41. An overview of incretin clinical trials.
Garber AJ; Spann SJ
J Fam Pract; 2008 Sep; 57(9 Suppl):S10-8. PubMed ID: 18786339
[TBL] [Abstract][Full Text] [Related]
42. Blood pressure-lowering effects of incretin-based diabetes therapies.
Lovshin JA; Zinman B
Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
[TBL] [Abstract][Full Text] [Related]
44. How to implement incretin therapy.
Cobble ME
J Fam Pract; 2008 Sep; 57(9 Suppl):S26-31. PubMed ID: 18786341
[TBL] [Abstract][Full Text] [Related]
45. Time to insulin in type-2 diabetes: high hurdles or Santiago way?
Rotella CM; Pala L
Acta Diabetol; 2008 Jun; 45(2):67-74. PubMed ID: 18408882
[TBL] [Abstract][Full Text] [Related]
46. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
Rizzo M; Rizvi AA; Spinas GA; Rini GB; Berneis K
Expert Opin Investig Drugs; 2009 Oct; 18(10):1495-503. PubMed ID: 19758106
[TBL] [Abstract][Full Text] [Related]
47. The importance of beta-cell management in type 2 diabetes.
Standl E
Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
[TBL] [Abstract][Full Text] [Related]
48. When oral agents fail: optimizing insulin therapy in the older adult.
Meece J
Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
[TBL] [Abstract][Full Text] [Related]
49. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Gilbert MP; Pratley RE
Am J Med; 2009 Jun; 122(6 Suppl):S11-24. PubMed ID: 19464424
[TBL] [Abstract][Full Text] [Related]
51. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
52. [Incretins in the treatment of diabetes].
Bulum T; Smircić-Duvnjak L; Car N; Metelko Z
Lijec Vjesn; 2008; 130(7-8):195-200. PubMed ID: 18979908
[TBL] [Abstract][Full Text] [Related]
53. The scientific evidence: vildagliptin and the benefits of islet enhancement.
Mathieu C
Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
[TBL] [Abstract][Full Text] [Related]
54. [Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV].
Perusicová J
Vnitr Lek; 2007 Sep; 53(9):1005-9. PubMed ID: 18019673
[TBL] [Abstract][Full Text] [Related]
55. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
Pratley RE
J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
[No Abstract] [Full Text] [Related]
56. Pharmacotherapy of hyperglycemia.
Kulasa KM; Henry RR
Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
[TBL] [Abstract][Full Text] [Related]
57. Mining incretin hormone pathways for novel therapies.
Wideman RD; Kieffer TJ
Trends Endocrinol Metab; 2009 Aug; 20(6):280-6. PubMed ID: 19595611
[TBL] [Abstract][Full Text] [Related]
58. Selecting among ADA/EASD tier 1 and tier 2 treatment options.
McGill JB
J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S26-34. PubMed ID: 19744422
[TBL] [Abstract][Full Text] [Related]
59. Incretin-based therapy and pancreatic beta cells.
Chon S; Riveline JP; Blondeau B; Gautier JF
Diabetes Metab; 2014 Dec; 40(6):411-22. PubMed ID: 25443548
[TBL] [Abstract][Full Text] [Related]
60. Incretin-based therapy in chronic kidney disease.
Pinelli NR; Moore CL; Tomasello S
Adv Chronic Kidney Dis; 2010 Sep; 17(5):439-49. PubMed ID: 20727514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
